Fin des groupes témoins (placebo) dans les essais clinique des vaccins
Covid-19 vaccines: In the rush for regulatory approval, do we need more data ? Peter Doshi, senior editor After rollout under emergency authorisation, manufacturers of covid-19 vaccines now have their sights on regulatory approval. But what’s the rush, asks Peter Doshi, and is just six months of data from now unblinded trials acceptable? In April 2021, Pfizer and Moderna announced […]
» Lire la suite